4月30日，据CDE官网消息，默沙东研发（中国）有限公司联合申请药品“注射用MK-2870”，获得临床试验默示许可，受理号CXSB2500040。
公示信息显示，药品“注射用MK-2870”适应症：非小细胞肺癌。
默沙东研发（中国）有限公司，成立于2012年，位于北京市，是一家以从事研究和试验发展为主的企业。企业注册资本2000万美元，实缴资本2000万美元。
通过天眼查大数据分析，默沙东研发（中国）有限公司参与招投标项目9次，专利信息3条，此外企业还拥有行政许可7个。
主要股东信息显示，默沙东研发（中国）有限公司由默沙东研发有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.